Auckland Cancer Society Research Centre

Targeting tumour (lymph)angiogenesis through adrenomedullin-1

Targeting tumour (lymph)angiogenesis through adrenomedullin-1

One of the hallmarks of cancer is increased formation of blood vessels (angiogenesis) and lymphatic vessels (lymphangiogenesis) and this process is mediated, in part, by a hormone known as adrenomedullin (AM). This project seeks to design and synthesize new agents that selectively modulate the ability of AM to promote angiogenesis. This target, known as the AM receptor, is found on the surface of cells. AM acts through this receptor to stimulate signalling and promote blood vessel growth.

In collaboration with Associate Professor Debbie Hay, School of Biological Sciences and Dr Jack Flanagan we are using medicinal chemistry, combined with molecular modelling, to create new molecules that block the access of AM to this groove and therefore reduce its activity in blood vessels. These molecules will be tested for their ability to selectively bind to the AM receptor and to stop AM signalling. This project represents the first steps towards identifying a new targeted anticancer therapy.


Financial support from the Health Research Council of NZ (logo), Auckland Medical Research Foundation (logo), Lottery Health Research (logo), and The University of Auckland Biopharma Thematic Research Initiative is gratefully acknowledged.